These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25239638)

  • 1. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
    Tao Y; Kim J; Faubel S; Wu JC; Falk SA; Schrier RW; Edelstein CL
    Proc Natl Acad Sci U S A; 2005 May; 102(19):6954-9. PubMed ID: 15863619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease.
    Belibi F; Ravichandran K; Zafar I; He Z; Edelstein CL
    Am J Physiol Renal Physiol; 2011 Jan; 300(1):F236-44. PubMed ID: 20943770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
    Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
    Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
    Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
    Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
    Tao Y; Kim J; Schrier RW; Edelstein CL
    J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.
    Zhang J; Jiang W; Liu W; Wu JJ; Song L; Cheng JX; Yao M; Yang LP; Yao DF
    Future Oncol; 2016 Feb; 12(4):515-24. PubMed ID: 26776341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.
    Ravichandran K; Zafar I; He Z; Doctor RB; Moldovan R; Mullick AE; Edelstein CL
    Hum Mol Genet; 2014 Sep; 23(18):4919-31. PubMed ID: 24847003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
    Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
    PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.
    Zhao L; Yue P; Khuri FR; Sun SY
    Cancer Res; 2013 Mar; 73(6):1946-57. PubMed ID: 23319802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
    Zafar I; Belibi FA; He Z; Edelstein CL
    Nephrol Dial Transplant; 2009 Aug; 24(8):2349-53. PubMed ID: 19321761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
    Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
    PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
    Buchholz B; Klanke B; Schley G; Bollag G; Tsai J; Kroening S; Yoshihara D; Wallace DP; Kraenzlin B; Gretz N; Hirth P; Eckardt KU; Bernhardt WM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.